Glymphatic Clearance, Norepinephrine Vasomotion, and Neurodegeneration Risk
1 Hauglund et al. 2025 — Norepinephrine Vasomotion Drives Glymphatic Clearance
Full Citation:: Hauglund NL, Andersen M, Tokarska K, et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025;188(3):606–622.e17. (Hauglund et al. 2025) DOI:: 10.1016/j.cell.2024.11.027 PMID:: 39788123 Study Design:: Multi-modal mechanistic study in freely behaving mice; fiber photometry, EEG/EMG, optogenetics, SPECT/CT neuroimaging; pharmacological intervention (zolpidem) Sample Size:: n=3–15 per condition across multiple experiments Key Findings::
- Tightly synchronized infraslow oscillations in norepinephrine (NE), cerebral blood volume (CBV), and CSF are the strongest predictors of glymphatic clearance during NREM sleep
- NE released from locus coeruleus (LC) drives slow rhythmic constriction and dilation of cerebral arteries (vasomotion); because CBV and CSF share the confined intracranial space, arterial contraction displaces CSF inward --- a hydraulic pump
- Optogenetic stimulation of LC induced anti-correlated changes in vasomotion and CSF signal; artificial arterial oscillations enhanced CSF inflow into brain parenchyma
- Zolpidem (common sleep aid) suppressed NE oscillations by ~50% and proportionally reduced glymphatic flow, despite maintaining sleep --- dissociating sleep duration from clearance efficacy
- Adrenergic receptor blockade (pan-adrenergic) eliminated LC-induced vascular effects, confirming NE-adrenergic signaling as the mechanistic driverConclusion:: The LC-NE axis is a master regulator of glymphatic clearance during sleep. Chronic autonomic dysfunction (including ME/CFS dysautonomia) and medications that suppress NE oscillations may directly impair brain waste clearance regardless of total sleep time. Limitations:: Mouse model; human validation pending; multiple experiments use small n; zolpidem effects in humans require dedicated study. ME/CFS Relevance:: ME/CFS involves documented LC/NE dysfunction (DHPG deficits in NIH deep phenotyping), autonomic dysregulation, and unrefreshing sleep. This paper provides the mechanistic chain: LC-NE dysfunction → impaired vasomotion → reduced glymphatic clearance → brain waste accumulation → cognitive symptoms and PEM amplification. Certainty Assessment::
- *Quality:* High (Cell; Nedergaard lab; multi-modal, mechanistic, interventional)
- *Sample:* Preclinical (mouse); human replication pending
- *Replication:* Not yet independently replicated in humans
- *Score:* 0.822 Fultz et al. 2019 — EEG/Hemodynamic/CSF Oscillations in Human Sleep
Full Citation:: Fultz NE, Bonmassar G, Setsompop K, et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science. 2019;366(6465):628–631. (Fultz et al. 2019) DOI:: 10.1126/science.aax5440 PMID:: 31672896 Study Design:: Observational human neuroimaging study; simultaneous EEG + accelerated fMRI measuring neural activity, hemodynamics, and fourth-ventricle CSF flow during sleep and wakefulness Sample Size:: n=13 subjects (sleep); n=11 (wakefulness); 129 analyzed sleep segments Key Findings::
- During NREM sleep, neural slow waves are followed by hemodynamic oscillations (CBV decrease), which are coupled to large inward pulses of CSF through the fourth ventricle --- one wave every ~20 seconds
- CSF waves during sleep are macroscopically visible and far larger than those during wakefulness (~4-second smaller waves while awake)
- The three signals (EEG slow waves → blood volume → CSF flow) form a temporally ordered, predictable cascade
- Provides the first direct human evidence that NREM slow wave activity mechanistically drives CSF clearanceConclusion:: Human confirmatory data showing that the glymphatic pump is engaged during NREM sleep and driven by the slow-wave EEG signature. NREM slow-wave deficits (documented in ME/CFS) would directly reduce this CSF pump activity. Limitations:: Small sample; MRI-based CSF measurement limited to fourth ventricle; cannot directly measure parenchymal clearance. ME/CFS Relevance:: Documents the human mechanism disrupted by ME/CFS unrefreshing sleep. Alpha intrusion into NREM and slow-wave deficits documented in ME/CFS would reduce the CSF pump oscillations measured here. Certainty Assessment::
- *Quality:* High (Science; MIT/MGH; human neuroimaging)
- *Sample:* n=13; small but high-quality
- *Replication:* Core finding replicated across multiple subsequent studies
- *Score:* 0.803 Holth et al. 2019 — Sleep-Wake Cycle Regulates Tau in ISF and Human CSF
Full Citation:: Holth JK, Fritschi SK, Wang C, et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880–884. (Holth et al. 2019) DOI:: 10.1126/science.aav2546 PMID:: 30679382 Study Design:: Combined mouse ISF microdialysis, human CSF sampling during acute sleep deprivation, chemogenetic wakefulness induction, tau seeding/spreading model Sample Size:: Human arm n=4–6; mouse arms n=6–16 per condition Key Findings::
- Brain ISF tau was ~90% higher during normal wakefulness vs.\ sleep; ~100% higher during sleep deprivation (SD) vs.\ sleep
- Human CSF tau increased >50% after one night of total sleep deprivation
- Chemogenetically driven wakefulness in mice significantly increased both ISF amyloid-β and tau
- Chronic SD enhanced tau pathology spreading in a tau seeding-and-spreading model, suggesting accumulation is not merely transient
- The wakefulness-tau link appears driven by increased neuronal activity (not just impaired clearance) --- both production and clearance axes are involvedConclusion:: Chronic sleep disruption, as occurs in ME/CFS, could drive progressive tau accumulation. The >50% human CSF tau increase from a single night of deprivation demonstrates acute sensitivity; chronic ME/CFS sleep deficit would be expected to produce sustained elevation. Limitations:: Human arm very small (n=4–6); mouse mechanistic data may not fully translate; long-term consequences of years-long disruption not directly studied; ME/CFS population not studied. ME/CFS Relevance:: Quantifies the neurodegeneration risk created by ME/CFS unrefreshing sleep. No study has yet measured whether ME/CFS patients accumulate tau/amyloid at accelerated rates — a critical research gap. Certainty Assessment::
- *Quality:* High (Science; Holtzman lab, WashU; human + mechanistic animal data)
- *Sample:* Human n=4--6 (very small); mouse n=6--16
- *Replication:* Core tau-sleep finding corroborated by Ju 2017 and Lucey/Holtzman subsequent work
- *Score:* 0.824 Ju et al. 2017 — Slow Wave Sleep Disruption Increases CSF Amyloid-β
Full Citation:: Ju Y-E S, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain. 2017;140(8):2104–2111. (Ju et al. 2017) DOI:: 10.1093/brain/awx148 PMID:: 28899014 Study Design:: Experimental SWA disruption via acoustic tones + lumbar CSF sampling in 22 participants aged 35–65; 6-night home actigraphy pre-sampling; cross-over design Sample Size:: n=22 (SWA disruption arm) Key Findings::
- Specific disruption of slow wave activity (SWA) strongly correlated with increased CSF amyloid-β 40 (r=0.610, p=0.009) and amyloid-β 42
- Total sleep time and overall sleep efficiency did not correlate with amyloid-β changes --- the quality of deep sleep architecture matters, not just duration
- Worse home sleep quality (6-night actigraphy) correlated with higher CSF tau (r=0.543, p=0.045)
- Suggests neuronal activity changes during disrupted deep sleep drive biomarker elevationConclusion:: The unrefreshing sleep in ME/CFS is characterized by impaired SWA (alpha intrusion, NREM microstructure abnormalities). This paper shows SWA disruption specifically elevates amyloid-β and tau, providing a direct link between ME/CFS sleep phenotype and neurodegeneration biomarkers. Limitations:: Single-night SWA disruption; n=22; long-term effects not assessed; ME/CFS patients not studied. ME/CFS Relevance:: The ME/CFS sleep deficit is quantitatively SWA-specific — exactly the parameter this study shows to elevate Alzheimer’s biomarkers. Certainty Assessment::
- *Quality:* High (Brain; Holtzman lab; experimental design with lumbar puncture)
- *Sample:* n=22; moderate
- *Replication:* Corroborated by Holth 2019
- *Score:* 0.785 Lee et al. 2015 — Body Posture and Glymphatic Transport
Full Citation:: Lee H, Xie L, Yu M, et al. The effect of body posture on brain glymphatic transport. Journal of Neuroscience. 2015;35(31):11034–11044. (Lee et al. 2015) DOI:: 10.1523/JNEUROSCI.1625-15.2015 PMID:: 26245965 Study Design:: Dynamic contrast-enhanced MRI with kinetic modeling in anesthetized rodents (supine/prone/lateral positions); validated with fluorescence microscopy and radioactive tracers Sample Size:: MRI arm: 24 rats; fluorescence/tracer arms: mice n=6–8 per group Key Findings::
- Lateral position produced most efficient glymphatic transport --- best CSF-ISF exchange, fastest amyloid-β clearance
- Prone position (mimicking upright/awake posture) showed tracer retention, slower clearance, more CSF efflux via large cervical vessels
- Supine position was intermediate
- Proposes lateral sleep preference across mammals may have evolved to optimize brain waste clearanceConclusion:: Sleep position is a modifiable factor affecting glymphatic efficiency. Lateral sleep may be particularly important for ME/CFS patients to maximize whatever glymphatic function remains. Limitations:: Anesthetized animals only; anesthesia itself affects glymphatic function (NE dynamics altered); human validation not yet published. ME/CFS Relevance:: Provides evidence-based sleep hygiene rationale. ME/CFS patients who frequently change position due to pain or OI may lose the positional glymphatic advantage. Certainty Assessment::
- *Quality:* High (J Neurosci; Nedergaard/Benveniste labs; multi-method validation)
- *Sample:* Rodent only; not replicated in humans
- *Replication:* Not yet confirmed in humans
- *Score:* 0.686 Hablitz & Nedergaard 2021 — The Glymphatic System: Fundamental Neurobiology Review
Full Citation:: Hablitz LM, Nedergaard M. The glymphatic system: a novel component of fundamental neurobiology. Journal of Neuroscience. 2021;41(37):7698–7711. (Hablitz and Nedergaard 2021) DOI:: 10.1523/JNEUROSCI.0619-21.2021 PMID:: 34526407 Study Design:: Invited review; comprehensive synthesis of glymphatic system biology from Nedergaard lab Key Findings::
- Describes structural basis: perivascular channels around arteries (CSF influx) and veins (ISF efflux), facilitated by AQP4 water channels on astrocytic endfeet
- Astrocyte and blood vessel geometry determines perivascular space shape and fluid transport rate; AQP4 deletion reduces clearance by ~70%
- Acute hypertension stiffens arterial walls, reduces pulsatility, and reduces perivascular fluid flow by up to 50%
- Cross-talk documented between glymphatic, cardiovascular, gastrointestinal, and lymphatic systems; positions glymphatic/lymphatic axis as a "cornerstone in signaling between the brain and body"Conclusion:: Authoritative review establishing the biological foundation for glymphatic-ME/CFS hypotheses. The cardiovascular cross-talk is directly relevant: ME/CFS cardiovascular dysfunction (reduced cardiac output, OI, POTS) reduces the arterial pulsatility driving glymphatic flow. Limitations:: Review article; primarily Nedergaard lab perspective; some aspects debated (magnitude of AQP4 contribution; bulk flow vs. diffusion controversy). ME/CFS Relevance:: Mechanistic foundation paper. Cardiovascular-glymphatic cross-talk explains why OI/POTS contributes to glymphatic failure via reduced cerebral perfusion and pulsatility. Certainty Assessment::
- *Quality:* High (J Neurosci review; authoritative primary lab)
- *Sample:* N/A (review)
- *Replication:* Core findings well-replicated; some contested
- *Score:* 0.787 Zhu et al. 2025 — Noradrenergic Modulation: Neuropsychiatric and Mortality Implications
Full Citation:: Zhu T-T, Yang J-J, Hashimoto K. Noradrenergic modulation of glymphatic clearance: implications for neuropsychiatric disorders and mortality. Molecular Psychiatry. 2025;30(9):4432–4434. (Zhu, Yang, and Hashimoto 2025) DOI:: 10.1038/s41380-025-03051-8 PMID:: 40399469 Study Design:: Perspective/commentary synthesizing Hauglund 2025 and clinical implications Key Findings::
- Confirms NE oscillation frequency during NREM sleep as the key predictor of glymphatic clearance
- Identifies drug classes that may impair glymphatic clearance via adrenergic blockade: zolpidem, orexin receptor antagonists (suvorexant, lemborexant), antipsychotics with adrenergic antagonism, anesthetics
- Zolpidem associated with increased dementia risk in elderly
- Calls for research on therapies restoring rhythmic vasomotion to enhance clearanceConclusion:: Many medications used in ME/CFS management (sleep aids, certain antipsychotics) may paradoxically worsen glymphatic function. Clinically significant warning. Limitations:: Commentary only; no primary data; extrapolates from mouse data to human clinical recommendations. ME/CFS Relevance:: Direct clinical implication: Z-drugs and alpha-adrenergic blocking agents used for ME/CFS sleep or cardiovascular management may suppress NE oscillations and reduce glymphatic clearance. Certainty Assessment::
- *Quality:* Medium (Mol Psychiatry; commentary without primary data)
- *Sample:* N/A
- *Replication:* Mechanistic drug effects not directly tested in humans
- *Score:* 0.628 Chaganti et al. 2025 — Glymphatic Dysfunction in Long COVID Neurocognitive Impairment
Full Citation:: Chaganti JR, Talekar TK, Brew BJ. Asymmetrical glymphatic dysfunction in patients with long Covid associated neurocognitive impairment — correlation with BBB disruption. BMC Neurology. 2025;25(1):112. (Chaganti, Talekar, and Brew 2025) DOI:: 10.1186/s12883-025-04133-4 PMID:: 40108491 Study Design:: Proof-of-concept comparative study; DTI-ALPS glymphatic index + Dynamic Contrast Enhanced BBB permeability (Ktrans); longitudinal at 3 and 12 months Sample Size:: 14 PASC subjects with cognitive impairment; 10 healthy controls; longitudinal n=10 patients Key Findings::
- Significant reduction in left-hemisphere DTI-ALPS index in PASC vs.\ controls ($p < 0.04$) --- asymmetrical glymphatic dysfunction
- Strong inverse correlation between white matter BBB permeability (Ktrans) and glymphatic index (rho=0.66, $p < 0.03$)
- DTI-ALPS values did not significantly change over 12 months --- persistent dysfunction
- First in vivo DTI-ALPS measurement of glymphatic function in Long COVID/PASCConclusion:: Long COVID brain fog is associated with measurable glymphatic dysfunction detectable by non-invasive MRI. The BBB-glymphatic correlation suggests a positive feedback loop relevant to ME/CFS. Limitations:: Very small sample (n=14); proof-of-concept only; single center; no non-COVID control; no tau/NfL biomarker data. ME/CFS Relevance:: Provides the methodological blueprint for an ME/CFS DTI-ALPS glymphatic study. BBB-glymphatic coupling mechanism is relevant to ME/CFS neuroinflammation findings. Certainty Assessment::
- *Quality:* Medium (BMC Neurology; proof-of-concept; small n)
- *Sample:* n=14
- *Replication:* Preliminary; not independently replicated
- *Score:* 0.559 Tang et al. 2025 — Glymphatic Function in Post-COVID Sleep Disorders: DTI-ALPS Longitudinal Study
Full Citation:: Tang YL, Chen HB, Liu P, Liao YH, Xie A. Glymphatic function alterations in sleep disorder patients post-COVID-19: a longitudinal DTI-ALPS study. Nature and Science of Sleep. 2025;17:1377–1390. (Tang et al. 2025) DOI:: 10.2147/NSS.S522745 PMID:: 40547338 Study Design:: Prospective longitudinal; 59 post-COVID subjects with new sleep disorder (COVID_SD) vs. 39 post-COVID without (COVID_NSD); DTI-ALPS at baseline and 2-month follow-up Sample Size:: n=59 (COVID_SD), n=39 (COVID_NSD) Key Findings::
- COVID_SD showed significantly lower bilateral DTI-ALPS vs.\ COVID_NSD at baseline: left 1.23± 0.08 vs.\ 1.29± 0.11 (p=0.033); right 1.29± 0.08 vs.\ 1.33± 0.11 (p=0.013)
- Strong negative correlation between glymphatic dysfunction and sleep quality: left r=--0.636 (p=0.0002); right r=--0.539 ($p < 0.0001$)
- 2-month follow-up: ALPS indices showed recovery trends paralleling improved sleepConclusion:: Post-viral sleep disorder tracks with glymphatic dysfunction in a biologically close model for ME/CFS. Recovery of sleep quality is associated with recovery of glymphatic function, suggesting reversibility. Limitations:: Single-center; no non-COVID insomnia control; DTI-ALPS reflects awake-state function only; no tau/NfL biomarkers; modest effect sizes. ME/CFS Relevance:: Post-viral sleep disorder → glymphatic dysfunction directly analogous to ME/CFS. Largest DTI-ALPS sleep-disorder study in post-COVID. Supports feasibility and rationale for an ME/CFS DTI-ALPS study. Certainty Assessment::
- *Quality:* Medium (Nature Sci Sleep; prospective but single-center)
- *Sample:* n=59 (COVID_SD); adequate
- *Replication:* Not independently replicated
- *Score:* 0.55